

Officers: Thomas W. Weimer, Assistant Vice President, (Qualifying Individual), Earl Lee, President, Application Type: New OFF License. Trans Atlantic Logistics Inc (OFF), 87-02 168th Place, Jamaica, NY 11432, Officer: Khalid Mahmud, President, (Qualifying Individual), Application Type: New OFF License.

Transportation Management Inc. (NVO & OFF), 13111 Atlantic Blvd., #1, Jacksonville, FL 32225, Officers: Mitchell D. Swanson, Vice President, (Qualifying Individual), Larry Berry, President, Application Type: New NVO & OFF License.

Warehouse Division of World Terminal and Distributing Corporation dba WTDC (NVO & OFF), 2801 NW. 74 Avenue, #100, Miami, FL 33122, Officer: Ralph Gazitua, President, (Qualifying Individual), Application Type: New NVO & OFF License.

By the Commission.

Dated: July 20, 2012.

Karen V. Gregory,
Secretary.

[FR Doc. 2012-18177 Filed 7-24-12; 8:45 am]

BILLING CODE 6730-01-P

FEDERAL MARITIME COMMISSION

Ocean Transportation Intermediary License Reissuances

The Commission gives notice that the following Ocean Transportation Intermediary licenses have been reissued pursuant to section 40901 of the Shipping Act of 1984 (46 U.S.C. 40101).

License No.: 016201N.

Name: Delta Line International, Inc.

Address: 7970 NW 56th Street, Miami, FL 33166.

Date Reissued: June 14, 2012.

License No.: 017267NF.

Name: Just In Time Services, Inc.

Address: 11380 NW 34th Street, Suite 100, Doral, FL 33178.

Date Reissued: June 21, 2012.

Vern W. Hill,

Director, Bureau of Certification and Licensing.

[FR Doc. 2012-18178 Filed 7-24-12; 8:45 am]

BILLING CODE 6730-01-P

FEDERAL MARITIME COMMISSION

Ocean Transportation Intermediary License Revocations

The Commission gives notice that the following Ocean Transportation Intermediary license has been revoked pursuant to section 40901 of the

Shipping Act of 1984 (46 U.S.C. 40101) effective on the date shown.

License No.: 016914N.

Name: Air Sea Cargo Network, Inc.

Address: 6345 Coliseum Way, Oakland, CA 94621.

Date Revoked: June 6, 2012.

Reason: Voluntary surrender of license.

Vern W. Hill,

Director, Bureau of Certification and Licensing.

[FR Doc. 2012-18179 Filed 7-24-12; 8:45 am]

BILLING CODE 6730-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-0001]

Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Cardiovascular and Renal Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the Agency on FDA's regulatory issues.

Date and Time: The meeting will be held on September 13, 2012, from 8 a.m. to 5 p.m.

Location: FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center (rm. 1503), 10903 New Hampshire Ave., Silver Spring, MD 20993-0002. Information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: <http://www.fda.gov/AdvisoryCommittees/default.htm>; under the heading "Resources for You," click on "Public Meetings at the FDA White Oak Campus." Please note that visitors to the White Oak Campus must enter through Building 1.

Contact Person: Kalyani Bhatt, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, WO31-2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX: 301-847-8533, email: CRDAC@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), to find out

information regarding FDA advisory committee information. A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's Web site at <http://www.fda.gov/AdvisoryCommittees/default.htm> and scroll down to the appropriate advisory committee link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

Agenda: During the morning session, the committee will discuss new drug application (NDA) 203009, lixivaptan, submitted by Cardiokine Biopharma, LLC, for the proposed indication of the treatment of symptomatic hypervolemic and euvoemic hyponatremia associated with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH), respectively.

During the afternoon session, the committee will discuss NDA 203826, phenylephrine hydrochloride injection, USP, submitted by West-Ward Pharmaceutical Corp., to increase blood pressure in acute hypotensive states, such as shock and peri-operative hypotension.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at <http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm>. Scroll down to the appropriate advisory committee link.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before August 29, 2012. Oral presentations from the public will be scheduled between approximately 10:30 a.m. to 11 a.m., and 3:30 p.m. to 4 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before August 21, 2012. Time allotted for each presentation may be limited. If